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Objectives 
 Review epidemiology 
 Work up of Thyroid nodules 
 Indications for FNAB 
 Evolving role of molecular markers 
 Management 
 Questions 
 
 Thyroid nodules  
 About t 5% of women and 
1% of men have palpable 
nodules 
 Increasing identification of 
“incidental” lesions  
 19-67% of randomly 
selected individuals 
 Cancer incidence is lower  
 5-15% 
 
 
Thyroid cancer risk - history 
 Age<20, >70 years 
 Painful, hoarseness 
 Male sex 
 Personal history of thyroid 
cancer 
 FDG-PET positive 
 
 Family history 
 Medullary carcinomas 
 Non-medullary cancer 
syndromes 
 Cowden’s syndrome 
 Familial Adenomatous 
Polyposis 
 Werner’s syndrome 
 
 Familial non-medullary 
cancer Radiation exposure 
Increases linearly 
from 6.5 too 
2000cGy 
 
 
Thyroid cancer risk - Exam 
 
 
 Hard, gritty, fixed 
 Enlarged lymph 
nodes in the lateral 
neck, posterior 
triangle or 
supraclavicular area 
• THYROID EXAM  
• Palpate from the back with 
neck in mild extension 
• Isthmus within 1 cm of 
cricoid 
Guidelines 
 The American Thyroid Association published 
updated guidelines in 2009 for the management 
of thyroid nodules and thyroid cancer 
 
 Evidence- based recommendations 
  Cooper DS et al.Thyroid, 19(11):1167 
Work-up 
 Blood tests  
 TSH in ALL patients - If subnormal – do 123I or 99mTc 
pertechnetate to evaluate for hot nodule 
 Thyroglobulin and calcitonin measurement not 
indicated 
 
 Imaging 
 Neck ultrasound in ALL patients 
 CT/MRI (for large lesions, suspected substernal 
goiter) 
Neck ultrasound 
 Identify nodules with 
higher a priori risk of 
cancer 
 Solid, hypoechoic 
 Fine, stippled calcification 
 Vascularity 
 Taller than wide 
 Evaluate for enlarged 
lymph nodes 
 Guide for FNA  
Schwartz textbook of Surgery, 2009 
FNAB 
 Fine-needle 
aspiration biopsy 
 Most accurate and 
cost-effective method 
 False-negative rate 2-
4% (variable) 
 Ultrasound guidance  
recommended for 
non-palpable, mostly 
cystic or those 
located posteriorly 
 
Indications for FNAB 
 Not indicated for purely cystic or  “hot” nodules 
 Indicated for all solid or mixed solid-cystic 
nodules ≥ 1cm 
 EXCEPTION: 
 High-risk history - Family history, external beam 
or ionizing radiation exposure, prior history, 
FDG-PET positive, known RET- mutation carrier 
  If > 5mm and has suspicious imaging features 
 Abnormal cervical node of any size 
What about multi-nodular goiter? 
 If 2 or more nodules > 1cm, those with 
suspicious u/s appearance should be 
aspirated preferentially 
 
 If none has suspicious u/s appearance or 
there are multiple similar looking nodules 
Aspirate the largest nodules only and observe the 
others with serial u/s exams 
Cooper DS et al.Thyroid, 19(11):1167 
FNAB – Bethesda classification 
 To address issues of variability, terminology  
 Revised at the “NCI Thyroid Fine Needle 
Aspiration State of the Science Conference” 
 
 Key points: 
 Optimum specimen – 6 follicles each containing 10-
15 cells from at least 2 aspirations 
 6 categories with varying risks of malignancy 
FNAB Classifications 
1) NON-DIAGNOSTIC 
 Risk of malignancy not known 
 Usually due to limited cellularity (mainly cystic 
nodules), no follicular cells, poor fixation 
 
 MANAGEMENT 
 Repeat FNA with u/s guidance 
 Consider thyroidectomy if repeated non-diagnostic 
biopsy and clinically or radiographically suspicious 
 
 
Baloch et al. Diag Cytopathol, 2008 
FNA Results and Risk of cancer 
 2) BENIGN 
 Risk of malignancy < 1% 
 Includes nodular goiter, thyroiditis, 
hyperplastic/adenomatoid nodule 
 
 MANAGEMENT 
 Follow up with repeat exam and U/S in 6-12 months 
 Repeat FNAB or excision if continued growth 
 No data to support thyroid hormone suppression 
Baloch et al. Diag Cytopathol, 2008 
FNA Results and Risk of cancer 
 3) FOLLICULAR LESION OR ATYPIA OF 
UNDETERMINED SIGNIFICANCE (FLUS/AUS) 
 Risk of malignancy 5-10% 
 Cannot be classified as clearly benign or follicular 
neoplasm 
 
 MANAGEMENT 
 Repeat FNAB and correlate with clinical and 
radiologic findings 
Baloch et al. Diag Cytopathol, 2008 
FNA Results and Risk of cancer 
 4) FOLLICULAR NEOPLASM, SUSPICIOUS 
FOR FOLLICULAR NEOPLASM 
 Risk of malignancy < 20-30% 
 Also includes non-papillary follicular-patterned lesions 
and Hürthle cell lesions/neoplasms 
 
 MANAGEMENT 
 Thyroid lobectomy for definitive pathology diagnosis 
 May need second surgery 
 
Baloch et al. Diag Cytopathol, 2008 
Example 
Follicular thyroid cancer Follicular neoplasm 
“microfollicular pattern” 
Molecular markers 
 Due to limitations of FNAB in this setting 
 Combinations better than single marker 
 Study of Combination of BRAF (V600E), RAS 
mutations, RET/PTC and PAX/PPARγ 
rearrangements in FNA samples – presence of any 
abnormality strongly predictive of cancer 
 Gene expression classifier, 167 genes – correctly 
classified 78/85 nodules with sensitivity of 92%, but 
specificity only 52% 
 Additional studies needed before routine use 
recommended 
Nikiforov Y et al. JCEM 2011 
Alexander EK et al. NEJM 2012 
FNA Results and Risk of cancer 
 5) SUSPICIOUS FOR MALIGNANCY 
 Risk of malignancy 50-75% 
 Most found to be follicular variant of papillary cancer, 
also includes lesions suspicious for medullary cancer, 
lymphoma or anaplastic cancer when there is not 
enough tissue to do confirmatory tests 
 
 MANAGEMENT 
 Thyroidectomy with frozen section 
 Repeat FNA with flow cytometry for lymphoma or 
calcitonin staining for medullary cancer 
Baloch et al. Diag Cytopathol, 2008 
FNA Results and Risk of cancer 
 6) THYROID CANCER 
 Risk of malignancy 100% 
 Various types 
 
 
 MANAGEMENT 
 Thyroidectomy and lymph node dissection (extent 
varies with type of tumor) 
Baloch et al. Diag Cytopathol, 2008 
Papillary thyroid cancer 
FNAB 
Orphan-Annie nuclei 
Clark OH et al. Endocrine Tumors, 2003 
Surgical specimen 
Medullary thyroid cancer 
 5% of thyroid cancers 
 25% familial (FMTC, 
MEN2A/2B)  
 calcitonin and carcino-
embryonic antigen (CEA), 
Cushing’s syndrome – 
from ectopic ACTH  
 Remember to screen for 
PHEOCHROMOCTOMA 
and hypercalcemia 
MTC, amyloid on FNA 
IHC with calcitonin Clark OH et al. Endocrine Tumors, 2003 
Flow chart 
Schwartz Textbook of surgery 2014, in press 
Is there a role for screening? 
 Non-medullary  
 U/S screening supported by 
 Cohort study of 15 families with FNMTC showing 
prevalence of thyroid nodules > 5mm to be 44%, and 
cancer rate 19.7% 
 Study of siblings with apparently sporadic disease 
showed prevalence of nodules of 38%, and cancer 
rate of 5.9% 
 Offer to all first-degree relatives at risk 
 Timing debated (10 years prior to index cancer?) 
 
Sadowski SM et al. Surgery 2013 
Rosario PW et al. Thyroid 2012 
Take-home points 
 Careful history and P/E with special attention to 
risk factors 
 All patients need TSH and neck ultrasound 
 FNA as indicated 
 Benign nodules still need follow up! 
 A follicular or Hurthle cell neoplasm is likely 
benign (80%) but needs lobectomy for diagnosis 
 Refer “suspicious for cancer” or 
“cancer”diagnoses for surgery 
Thank you 
 Questions? 
